Recent developments include the company's commencement of trading on the OTCQX market, enhancing its visibility and access to investors.

• Aesthetic Medical International Holdings Group Ltd commenced trading on the OTCQX market as of July 10, 2024 [N1].
• OTC Markets Group officially welcomed Aesthetic Medical International Holdings Group Ltd to OTCQX on July 10, 2024 [N2].

The company has demonstrated operational resilience with only minor declines in revenue and treatment cases despite a challenging market environment. Improvements in EBITDA and adjusted EBITDA margins suggest enhanced cost management and operational efficiency. The shift toward non-surgical aesthetic treatments aligns with broader industry trends favoring less invasive procedures. The recent commencement of OTCQX trading may improve market access and investor awareness, supporting future capital raising and strategic initiatives.

The company faces challenges including a decline in active customers and treatment cases, reflecting reduced advertising expenditures and market consumption softness. The net current liability position and low liquidity ratios highlight potential financial constraints. The net loss, although reduced, persists, and the company operates in a competitive market with sensitivity to consumer discretionary spending. Promotional campaigns have led to lower average spending per customer, which may pressure margins further.

The company's moat is supported by its established presence in key urban regions of China, a diversified service portfolio covering surgical and non-surgical aesthetic treatments, and over two decades of clinical experience. Operational improvements such as the implementation of the 7S On-Site Management Method aim to enhance service quality and customer experience, potentially strengthening competitive positioning. However, the aesthetic medical services market is competitive and sensitive to consumer spending trends, which may impact growth and profitability.

• Market Consumption Sensitivity: The aesthetic medical services sector is sensitive to changes in consumer discretionary spending, which can impact demand for treatments and revenue.
• Liquidity Constraints: The company has a current ratio of 0.51 and a cash ratio of 0.11 as of December 31, 2024, indicating potential liquidity challenges and net current liabilities.
• Competitive Environment: Competition from other aesthetic service providers and shifts in consumer preferences may affect market share and pricing power.
• Operational Execution: The effectiveness of operational improvements such as the 7S On-Site Management Method in sustaining service quality and customer satisfaction is critical to maintaining competitive positioning.

• Aesthetic Medical International Holdings Group Ltd (PAIYY) is a leading provider of aesthetic medical services in China, operating treatment centers mainly in the Guangdong-Hong Kong-Macau Greater Bay area and the Yangtze River Delta area [S2].
• The company offers a range of services including surgical aesthetic treatments, non-surgical aesthetic treatments, general medical services, and other aesthetic services [S2].
• For the six months ended June 30, 2025, total revenue was RMB350.6 million (USD48.9 million), a 3.5% decrease from the same period in 2024 [S2].
• Gross profit for the same period was RMB149.7 million (USD20.9 million), down 6.1% year-over-year, with a gross margin of 42.7%, a decline of 1.2 percentage points [S2].
• Selling, general and administrative expenses decreased by 17.8% to RMB145.6 million (USD20.3 million), representing 41.5% of revenue, down from 48.8% in the prior year period [S2].
• EBITDA increased to RMB26.4 million (USD3.7 million) from RMB13.9 million in the first half of 2024, and adjusted EBITDA rose to RMB35.3 million (USD4.9 million) from RMB16.0 million [S2].
• The company recorded a net loss of RMB9.8 million (USD1.4 million) for the first half of 2025, an improvement from a net loss of RMB22.4 million in the first half of 2024 [S2].
• Basic and diluted loss per share were RMB0.06 (USD0.01) for the first half of 2025, compared with RMB0.15 in the prior year period [S2].
• The total number of active customers decreased by 6% year-over-year to 124,342 in the first half of 2025, with new customers down 10% and repeat customers down 4% [S2].
• The total number of treatment cases declined by 2.3% to 322,911, with non-surgical aesthetic treatments increasing as a proportion of total treatments by 3.6 percentage points [S2].
• Average spending per customer decreased by 1.2% to RMB1,086, attributed to increased promotional campaigns including discounted live streaming e-commerce offers [S2].
• The company implemented the 7S On-Site Management Method to improve operational efficiency and service quality, focusing on cleanliness and organization of treatment and consultation areas [S2].
• As of December 31, 2024, cash and cash equivalents were RMB42.8 million, current assets were RMB206.2 million, and current liabilities were RMB402.0 million, resulting in a current ratio of 0.51 and a cash ratio of 0.11 [S1].
• The company had total equity of RMB1.89 million as of June 30, 2025, with total liabilities of RMB484.6 million, indicating a net current liability position [S2].
• Aesthetic Medical International Holdings Group Ltd commenced trading on the OTCQX market as of July 10, 2024 [N1][N2].